KR20030079604A - The composition of improved materials in treating alcohol hangover and boosting an energy. - Google Patents
The composition of improved materials in treating alcohol hangover and boosting an energy. Download PDFInfo
- Publication number
- KR20030079604A KR20030079604A KR1020020018765A KR20020018765A KR20030079604A KR 20030079604 A KR20030079604 A KR 20030079604A KR 1020020018765 A KR1020020018765 A KR 1020020018765A KR 20020018765 A KR20020018765 A KR 20020018765A KR 20030079604 A KR20030079604 A KR 20030079604A
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- asparagine
- plants
- parts
- licorice
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 206010019133 Hangover Diseases 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- 241000196324 Embryophyta Species 0.000 claims abstract description 20
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 19
- 241001465754 Metazoa Species 0.000 claims abstract description 11
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 5
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 5
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 5
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 4
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 22
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 21
- 235000019441 ethanol Nutrition 0.000 claims description 20
- 229960003638 dopamine Drugs 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 18
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 16
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 16
- 229940010454 licorice Drugs 0.000 claims description 16
- 241000202807 Glycyrrhiza Species 0.000 claims description 15
- 235000013336 milk Nutrition 0.000 claims description 13
- 239000008267 milk Substances 0.000 claims description 13
- 210000004080 milk Anatomy 0.000 claims description 13
- 241001107116 Castanospermum australe Species 0.000 claims description 11
- 235000021279 black bean Nutrition 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- 238000001784 detoxification Methods 0.000 claims description 10
- -1 Calcimal malat Chemical compound 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- UPJFTVFLSIQQAV-UHFFFAOYSA-N Sedanolide Chemical compound C1CCC2C(CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-UHFFFAOYSA-N 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 239000000341 volatile oil Substances 0.000 claims description 5
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 claims description 4
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000004378 Glycyrrhizin Substances 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 229960001231 choline Drugs 0.000 claims description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 4
- HEMSJKZDHNSSEW-UHFFFAOYSA-N o-orsellinate depside Chemical compound CC1=CC(O)=CC(O)=C1C(=O)OC1=CC(C)=C(C(O)=O)C(O)=C1 HEMSJKZDHNSSEW-UHFFFAOYSA-N 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 210000003056 antler Anatomy 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 210000004207 dermis Anatomy 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 2
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 claims description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- 239000004382 Amylase Substances 0.000 claims description 2
- 102000013142 Amylases Human genes 0.000 claims description 2
- 108010065511 Amylases Proteins 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 2
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 claims description 2
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims description 2
- 241000190633 Cordyceps Species 0.000 claims description 2
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 claims description 2
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 claims description 2
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- YJHVMPKSUPGGPZ-UHFFFAOYSA-N Dihydro-beta-eudesmol Natural products C1CC(C(C)(C)O)CC2C(C)CCCC21C YJHVMPKSUPGGPZ-UHFFFAOYSA-N 0.000 claims description 2
- LLKXNMNOHBQSJW-UHFFFAOYSA-N Elemol Natural products CCC(=C)C1CC(C=CC1(C)C)C(C)(C)O LLKXNMNOHBQSJW-UHFFFAOYSA-N 0.000 claims description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 2
- 239000000899 Gutta-Percha Substances 0.000 claims description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 claims description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 2
- HXCGUCZXPFBNRD-DNLMCPORSA-N Nodakenin Chemical compound CC(C)([C@@H]1OC2=CC=3OC(=O)C=CC=3C=C2C1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HXCGUCZXPFBNRD-DNLMCPORSA-N 0.000 claims description 2
- HXCGUCZXPFBNRD-QVYYAULWSA-N Nodakenin Natural products O(C(C)(C)[C@@H]1Oc2c(cc3c(OC(=O)C=C3)c2)C1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HXCGUCZXPFBNRD-QVYYAULWSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 240000006079 Schisandra chinensis Species 0.000 claims description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 2
- UFCGDBKFOKKVAC-DSASHONVSA-N Schisantherin A Chemical compound O([C@H]1C=2C=C(C(=C(OC)C=2C2=C(OC)C=3OCOC=3C=C2C[C@H](C)[C@@]1(O)C)OC)OC)C(=O)C1=CC=CC=C1 UFCGDBKFOKKVAC-DSASHONVSA-N 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- IPZIYGAXCZTOMH-UHFFFAOYSA-N alpha-eudesmol Natural products CC1=CCCC2CCC(CC12)C(C)(C)O IPZIYGAXCZTOMH-UHFFFAOYSA-N 0.000 claims description 2
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 235000019418 amylase Nutrition 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- 229960005261 aspartic acid Drugs 0.000 claims description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 2
- XFSVWZZZIUIYHP-UHFFFAOYSA-N beta-Eudesmol Natural products CC(C)(O)C1CCC2CCCC(=C)C2C1 XFSVWZZZIUIYHP-UHFFFAOYSA-N 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- BOPIMTNSYWYZOC-VNHYZAJKSA-N beta-eudesmol Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(C)(O)C)CC[C@]21C BOPIMTNSYWYZOC-VNHYZAJKSA-N 0.000 claims description 2
- 229960003237 betaine Drugs 0.000 claims description 2
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 claims description 2
- 229940074393 chlorogenic acid Drugs 0.000 claims description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 2
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 2
- GFJIQNADMLPFOW-UHFFFAOYSA-N cis-Elemol Natural products CC(=C)C1CC(C(C)(C)O)CCC1(C)C=C GFJIQNADMLPFOW-UHFFFAOYSA-N 0.000 claims description 2
- 229940043350 citral Drugs 0.000 claims description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 2
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims description 2
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims description 2
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 claims description 2
- GFJIQNADMLPFOW-VNHYZAJKSA-N elemol Chemical compound CC(=C)[C@@H]1C[C@H](C(C)(C)O)CC[C@@]1(C)C=C GFJIQNADMLPFOW-VNHYZAJKSA-N 0.000 claims description 2
- 229960003399 estrone Drugs 0.000 claims description 2
- 229940074391 gallic acid Drugs 0.000 claims description 2
- 235000004515 gallic acid Nutrition 0.000 claims description 2
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 claims description 2
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 229930186755 gomisin Natural products 0.000 claims description 2
- 229920000588 gutta-percha Polymers 0.000 claims description 2
- 229940025878 hesperidin Drugs 0.000 claims description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 2
- 229940087305 limonene Drugs 0.000 claims description 2
- 235000001510 limonene Nutrition 0.000 claims description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000009498 luteolin Nutrition 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229940043353 maltol Drugs 0.000 claims description 2
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 claims description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims description 2
- 229940052490 naringin Drugs 0.000 claims description 2
- 229930019673 naringin Natural products 0.000 claims description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 2
- HXCGUCZXPFBNRD-UHFFFAOYSA-N nodakenine Natural products C1C2=CC=3C=CC(=O)OC=3C=C2OC1C(C)(C)OC1OC(CO)C(O)C(O)C1O HXCGUCZXPFBNRD-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000018553 tannin Nutrition 0.000 claims description 2
- 229920001864 tannin Polymers 0.000 claims description 2
- 239000001648 tannin Substances 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 claims 2
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 claims 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 claims 1
- PKYUNJWBVAXPMG-UHFFFAOYSA-N 3-ethoxy-2-hydroxybenzoic acid Chemical compound CCOC1=CC=CC(C(O)=O)=C1O PKYUNJWBVAXPMG-UHFFFAOYSA-N 0.000 claims 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims 1
- 244000061520 Angelica archangelica Species 0.000 claims 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 1
- 240000008067 Cucumis sativus Species 0.000 claims 1
- 235000009849 Cucumis sativus Nutrition 0.000 claims 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- TZJALUIVHRYQQB-UHFFFAOYSA-N Icarin Chemical compound C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 244000241838 Lycium barbarum Species 0.000 claims 1
- 235000015459 Lycium barbarum Nutrition 0.000 claims 1
- POIRVLZGTSWEMG-UHFFFAOYSA-N Magnoflorin Natural products N1CCC2=CC(OC)=C(O)C3=C2C1CC1=CC=C(OC)C(O)=C13 POIRVLZGTSWEMG-UHFFFAOYSA-N 0.000 claims 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 1
- 240000000342 Palaquium gutta Species 0.000 claims 1
- 235000014443 Pyrus communis Nutrition 0.000 claims 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 229940091250 magnesium supplement Drugs 0.000 claims 1
- AMBQHHVBBHTQBF-DLXIZZNVSA-N methyl 6-hydroxy-7-methyl-1-[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate Chemical compound C12C(C)C(O)CC2C(C(=O)OC)=COC1O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O AMBQHHVBBHTQBF-DLXIZZNVSA-N 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 229940124513 senna glycoside Drugs 0.000 claims 1
- 229930186851 sennoside Natural products 0.000 claims 1
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 4
- 241000209020 Cornus Species 0.000 abstract description 3
- 240000002045 Guettarda speciosa Species 0.000 abstract description 3
- 244000068988 Glycine max Species 0.000 abstract description 2
- 235000010469 Glycine max Nutrition 0.000 abstract description 2
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 abstract description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 3
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 3
- 244000003377 Allium tuberosum Species 0.000 abstract 1
- 235000005338 Allium tuberosum Nutrition 0.000 abstract 1
- 244000248539 Asparagus cochinchinensis Species 0.000 abstract 1
- 235000009292 Asparagus cochinchinensis Nutrition 0.000 abstract 1
- 241000255789 Bombyx mori Species 0.000 abstract 1
- 241000555678 Citrus unshiu Species 0.000 abstract 1
- 244000295848 Citrus x nobilis Species 0.000 abstract 1
- 235000017102 Citrus x nobilis Nutrition 0.000 abstract 1
- 241000533367 Cnidium officinale Species 0.000 abstract 1
- 241001264174 Cordyceps militaris Species 0.000 abstract 1
- 241000759833 Cornus officinalis Species 0.000 abstract 1
- 240000008955 Dioscorea japonica Species 0.000 abstract 1
- 235000005251 Dioscorea japonica Nutrition 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 235000008584 Hovenia dulcis Nutrition 0.000 abstract 1
- 244000010000 Hovenia dulcis Species 0.000 abstract 1
- 244000167230 Lonicera japonica Species 0.000 abstract 1
- 235000017617 Lonicera japonica Nutrition 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 241000208343 Panax Species 0.000 abstract 1
- 235000002791 Panax Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 241000691199 Taraxacum platycarpum Species 0.000 abstract 1
- 244000237330 gutta percha tree Species 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 13
- 230000009471 action Effects 0.000 description 10
- 239000012267 brine Substances 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 239000000843 powder Substances 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000001630 malic acid Substances 0.000 description 5
- 235000011090 malic acid Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- WLNGPDPILFYWKF-OAHLLOKOSA-N (-)-beta-chamigrene Chemical compound C1CC(C)=CC[C@]21C(C)(C)CCCC2=C WLNGPDPILFYWKF-OAHLLOKOSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 229940076810 beta sitosterol Drugs 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 229950005143 sitosterol Drugs 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- ASHVULSQMDWKFO-UHFFFAOYSA-N 5-(methoxymethyl)furan-2-carbaldehyde Chemical compound COCC1=CC=C(C=O)O1 ASHVULSQMDWKFO-UHFFFAOYSA-N 0.000 description 2
- MQBFFYQCZCKSBX-UHFFFAOYSA-N 5-hydroxy-6,7,8-trimethoxy-2-(3,4,5-trimethoxyphenyl)chromen-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2OC3=C(OC)C(OC)=C(OC)C(O)=C3C(=O)C=2)=C1 MQBFFYQCZCKSBX-UHFFFAOYSA-N 0.000 description 2
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 2
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 2
- 241000361919 Metaphire sieboldi Species 0.000 description 2
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 2
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 2
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 1
- NFZYDZXHKFHPGA-UHFFFAOYSA-N 17alpha-hydroxygofruside Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NFZYDZXHKFHPGA-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- QXQFFGOMXYKNBA-UHFFFAOYSA-N Chikusetsusaponin V Natural products CC1(C)CCC2(CCC3C(=CCC4C3(C)CCC5C(C)(C)C(CCC45C)OC6OC(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O QXQFFGOMXYKNBA-UHFFFAOYSA-N 0.000 description 1
- NFZYDZXHKFHPGA-QQHDHSITSA-N Chikusetsusaponin-V Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NFZYDZXHKFHPGA-QQHDHSITSA-N 0.000 description 1
- UXDIXFDKSPCUIX-AXFHLTTASA-N Cnidilide Chemical compound C1=CCC[C@@H]2[C@H](CCCC)OC(=O)[C@@H]21 UXDIXFDKSPCUIX-AXFHLTTASA-N 0.000 description 1
- 206010065420 Coronary artery dilatation Diseases 0.000 description 1
- CUKSFECWKQBVED-INIZCTEOSA-N Decursin Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-INIZCTEOSA-N 0.000 description 1
- BGXFQDFSVDZUIW-UHFFFAOYSA-N Decursinol Natural products O1C(=O)C=CC2=C1C=C1OC(C)(C)C(O)CC1=C2 BGXFQDFSVDZUIW-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229930188400 Gardenin Natural products 0.000 description 1
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 1
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 description 1
- CUKSFECWKQBVED-UHFFFAOYSA-N Grandivittin Natural products C1=CC(=O)OC2=C1C=C1CC(OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 1
- UPJFTVFLSIQQAV-KOLCDFICSA-N Neocnidilide Chemical compound C1CC[C@H]2[C@H](CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-KOLCDFICSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- VLXDPFLIRFYIME-MWHZVNNOSA-N alpha-Ylangene Chemical compound C1C=C(C)C2[C@@]3(C)CCC(C(C)C)C2C31 VLXDPFLIRFYIME-MWHZVNNOSA-N 0.000 description 1
- VLXDPFLIRFYIME-QRTUWBSPSA-N alpha-ylangene Natural products C1C=C(C)[C@@H]2[C@@]3(C)CC[C@@H](C(C)C)[C@@H]2[C@H]31 VLXDPFLIRFYIME-QRTUWBSPSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003716 antitrichomonal agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229950005197 butylphthalide Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001362 calcium malate Substances 0.000 description 1
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 description 1
- 229940016114 calcium malate Drugs 0.000 description 1
- 235000011038 calcium malates Nutrition 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- UXDIXFDKSPCUIX-UHFFFAOYSA-N condilide Natural products C1=CCCC2C(CCCC)OC(=O)C21 UXDIXFDKSPCUIX-UHFFFAOYSA-N 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- JXZWWIMXTVJNSF-UHFFFAOYSA-N decursin Natural products CC(=CC(=O)OC1Oc2cc3OC(=O)C=Cc3cc2CC1(C)C)C JXZWWIMXTVJNSF-UHFFFAOYSA-N 0.000 description 1
- BGXFQDFSVDZUIW-LBPRGKRZSA-N decursinol Chemical compound O1C(=O)C=CC2=C1C=C1OC(C)(C)[C@@H](O)CC1=C2 BGXFQDFSVDZUIW-LBPRGKRZSA-N 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- OGYXOOJUJQIDOX-UHFFFAOYSA-N epimedoside A Natural products OC1C(O)C(O)C(C)OC1OC1=C(C=2C=CC(O)=CC=2)OC2=C(CC=C(C)C)C(OC3C(C(O)C(O)C(CO)O3)O)=CC(O)=C2C1=O OGYXOOJUJQIDOX-UHFFFAOYSA-N 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 1
- RBRANZURTULKJD-UHFFFAOYSA-N ginsenoside Ro Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(C)(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C(C)(C)C5CCC34C)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O RBRANZURTULKJD-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000009377 nuclear transmutation Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229930183325 senkyunolide Natural products 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- JKQXZKUSFCKOGQ-QAYBQHTQSA-N zeaxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-QAYBQHTQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 약용 동ㆍ식물의 약성분에 도파민(dopamine)을 첨가하여 3단계의 공정 과정을 거쳐 배합 및 법제된 제약상의 허용 가능한 조성물에 관한 것이다. 특히 아래 1), 2), 3) 항의 약성분이 상호 상승작용을 할 수 있도록 디엘-아스파라긴(DL-Asparagine)을 포함하여 조성한 것이다.The present invention relates to a pharmaceutically acceptable composition formulated and formulated through a three step process by adding dopamine to the medicinal components of medicinal animals and plants. In particular, the drug components of 1), 2) and 3) below are made to include DL-asparagine (DL-Asparagine) to synergize with each other.
1) 1단계는 약용 식물의 약성분을 50메쉬(mesh)로 절편한 홍삼(紅蔘 ; 주성분-Ginsenoside Ro, Ra-Rh, panaxynal,β-Elemen,β-sitosterol, Amino acid, peptides, Maltol, choline), 구기자(枸杞子 ; 주성분-Betaine, Vitamin B1, Zeaxanthine, Physaline), 영지(靈芝 ; 주성분-Gyrophoric acid, Lecanoric acid), 지구자(枳子 ; 주성분-Glucose, Calcium malate), 청피(靑皮 ; 주성분-d-Limonene, Hesperidin, Naringin, Aspartic acid), 포공영(蒲公英 ; 주성분-Taraxacin, Taraxarol, Asparagin), 치자(梔子 ; 주성분-Geniposide, Genipin, Gardenoside, Crocin, Crocetin, Gardenin, Pectin), 갈근(葛根 ; 주성분-Starch,Daidzein, Daidzin, puerarin), 감초(甘草;주성분-Glycyrrhizin Liquiritigenin, Glucose, Mannitol, Malic acid, ℓ-Asparagin), 천궁(川芎 ; 주성분-Ligustilide, Butylidenphthalide, Butylphthalide, Neocnidilide, Cnidilide, Sedanolide, Senkyunolide 등을 주로한 정유)을 각각 평량하고 취하여 추출(抽出)한 약성분이다.1) In the first step, red ginseng is divided into 50 meshes of the medicinal plant. (Ginsenoside Ro, Ra-Rh, panaxynal, β- Elemen, β- sitosterol, Amino acid, peptides, Maltol, choline), Gugija (枸杞 子; main ingredient-Betaine, Vitamin B 1 , Zeaxanthine, Physaline), Ganoderma lucidum (靈 芝; main ingredient-Gyrophoric acid, Lecanoric acid) 子; Main ingredient-Glucose, Calcium malate, Cheongpi (靑 皮-Main ingredient-d-Limonene, Hesperidin, Naringin, Aspartic acid), Pogongyoung (Main ingredient-Taraxacin, Taraxarol, Asparagin), Gardenia (梔子; Main ingredient-Geniposide, Genipin , Gardenoside, Crocin, Crocetin, Gardenin, Pectin), Brown root;川芎: It is a medicinal ingredient extracted by weighing and extracting the main ingredients-essential oils mainly including Ligustilide, Butylidenphthalide, Butylphthalide, Neocnidilide, Cnidilide, Sedanolide, and Senkyunolide.
2) 2단계는 약용 동ㆍ식물을 1)에서와 같이 산수유(山茱萸 ; 주성분-Morroniside, Loganin, Cornin, Gallic acid, Malic acid), 두충(杜; 주성분-Gutta-Percha, Kotose, Chlorogenic acid, Pectin), 동충하초(冬夏草 ; 주성분-Cordycepic acid, Cordycepin), 구자(子 ; 주성분-Allycysteine Sulfoxide, Vitamin C), 오가피(五加皮 ; 주성분-Acanthoside A, B, C, D, Daucosterol, Polyacetylenes, Ziliodendlin,β-Sitosterol, Campesterol, Ethoxy-hydroxy-benzoid acid), 당귀(當歸 ; 주성분-Decursin, Decursinol, Nodakenin 등의 Coumarin 유도체와α-Pinene, Limonene,β-Eudesmol, Elemol 등을 주로한 정유), 녹용(鹿茸 ; 주성분-교질(膠質), Protein, Phosphate, Calcium, Magnesium, Estrone), 감초(甘草 ; 주성분-Glycyrrhizin, Liquiritigenin, Glucose, Mannitol, Malic acid, ℓ-Asparagin)를 각각 평량하고 취하여 추출한 약성분이다.2) In the second stage, medicinal animals and plants are treated with cornus (山茱萸; main components-Morroniside, Loganin, Cornin, Gallic acid, Malic acid), ; Main ingredient-Gutta-Percha, Kotose, Chlorogenic acid, Pectin), Cordyceps sinensis 夏 草; Main ingredients-Cordycepic acid, Cordycepin), Guja ( 子; Main ingredient-Allycysteine Sulfoxide, Vitamin C), Ogapi (五加皮; Main ingredient-Acanthoside A, B, C, D, Daucosterol, Polyacetylenes, Ziliodendlin, β- Sitosterol, Campesterol, Ethoxy-hydroxy-benzoid acid), Angelica (當歸; Main ingredient-Coumarin derivatives such as Decursin, Decursinol, Nodakenin, essential oils mainly composed of α -Pinene, Limonene, β -Eudesmol, Elemol, etc.), Deer Antler (鹿 茸), Protein, Phosphate, Calcium, Magnesium, Estrone ), Licorice (甘草; the main ingredients-Glycyrrhizin, Liquiritigenin, Glucose, Mannitol, Malic acid, ℓ-Asparagin) are each extracted by weight and take.
3) 3단계는 1)에서와 같이 산약(山藥 ; 주성분-Saponin, Mucin, Arginine, Allantoin, Amylase, Choline), 진피(秦皮; 주성분-Aesculetin, Aesculin), 천문동(天門冬 ; 주성분-Asparasaponin Ⅳ,-Ⅴ,-Ⅵ,-Ⅶ, Asparagine,β-sitosterol, 5-Methoxymethylfurfural), 음양곽(淫羊藿 ; 주성분-Icariin, des-o-Methylicariin, Magnoflorine), 백강잠(白蠶 ; 주성분-Lipoprotein), 오미자(五味子 ; 주성분-Schizandrin, Gomisin A∼Q, Citral,α-Ylangene, Citric acid, Malic acid,β-Chamigrene, Citric acid, Malic acid,β-Chamigrene, Fatty Oil), 금은화(金銀花 ; 주성분-Inositol, Luteolin, Tannin), 감초(甘草 ; 주성분-Glycyrrhizin, Liquiritigenin, Glucose, Mannitol, Malic acid, ℓ-Asparagin), 흑두(黑豆 ; 주성분-Protein, Fatty Oil)를 각각 평량하고 취하여 추출한 약성분이다.3) In the third step, as in 1), the medicine (山藥; main ingredient-Saponin, Mucin, Arginine, Allantoin, Amylase, Choline), dermis (秦 皮; main ingredient-Aesculetin, Aesculin), Astronomical (天 門冬; main ingredient-Asparasaponin IV, -V, -VI, -Ⅶ, Asparagine, β -sitosterol, 5-Methoxymethylfurfural), Yin and Yang Guk (淫羊藿; main components-Icariin, des-o-Methylicariin, Magnoflorine) 蠶; Main ingredient-Lipoprotein, Schizandrin, Gomisin A-Q, Citral, α- Ylangene, Citric acid, Malic acid, β- Chamigrene, Citric acid, Malic acid, β- Chamigrene, Fatty Oil金 銀花; main ingredients-Inositol, Luteolin, Tannin), licorice (甘草; main ingredients-Glycyrrhizin, Liquiritigenin, Glucose, Mannitol, Malic acid, ℓ-Asparagin), black bean (黑豆; main ingredients-Protein, Fatty Oil) Extracted medicine ingredient.
본 발명의 조성물은 1단계, 2단계, 3단계의 공정과정을 거쳐 약용 동ㆍ식물의 100여 종류의 약성분이 상호 상승작용(相乘作用)을 할 수 있도록 도파민(dopamine)과 디엘-아스파라긴(DL-Asparagine)을 가하여 에틸알콜(Ethyl alcohol)로 추출(抽出)하여 숙성(熟成) 제조된 조성물이다. 약용 동ㆍ식물의 약효 성분은 수용성(水溶性)과 유용성(油溶性)으로 구성되어 있다. 종래는 약용 동ㆍ식물을 적당히 절편하여 약탕기에서 물을 붓고 끓여서 일정량으로 될 때 마포청에 넣고 짜서 복용하였다. 따라서 약용성분인 유용성은 복용할 수가 없었다. 본 발명에서는 발명의 구성에서와 같이 약용 동ㆍ식물을 절편 하여 법제(法制)<약효 성분중의 독성을 제거하고 약의 성분을 향상시키기 위한 비법> 한 후 50메쉬(mesh)정도 분말로 하고The composition of the present invention is a dopamine (Dopamine) and DL-asparagine so that more than 100 kinds of medicinal components of medicinal animals and plants through the process of steps 1, 2, 3 (DL-Asparagine) is added, extracted with ethyl alcohol (抽出) is a composition prepared by aging (maturation). The active ingredient of medicinal animals and plants is composed of water solubility and oil solubility. Conventionally, medicinal animals and plants are appropriately sliced, poured into a boiling water bath, boiled, and brought to a certain amount when squeezed into Mapocheong. Therefore, medicinal usefulness could not be taken. In the present invention, as in the constitution of the invention, medicinal animals and plants are sliced to obtain a <mesh recipe> to remove the toxicity in the active ingredient and to improve the composition of the drug>
도파민(dopamine=3-Hydroxytyramine)과 디엘-아스파라긴(DL-Asparagine=H 2 NCOCH 2 CH(NH 2)CO 2ㆍHㆍH 2 O)을 적량 가하여 에틸 알콜(Ethyl alcohol)로 추출 농축 건조하기 때문에 약용 동ㆍ식물이 가지고 있는 수용성 및 유용성의 약성분이 거의 추출되는 것이다. 또한 200메쉬 이상 분말로 하여 정제나 캅셀(capsule)로 하기 때문에 사람이 복용하기 쉬운 것이다.Dopamine (dopamine = 3-Hydroxytyramine) and DL-Asparagine (DL-Asparagine = H 2 NCOCH 2 CH ( NH 2 ) CO 2 ㆍ H ㆍ H 2 O ) are added to the mixture, and extracted with ethyl alcohol. Water-soluble and oil-soluble medicinal ingredients of medicinal animals and plants are almost extracted. In addition, since it is a powder or tablet (capsule) to more than 200 mesh powder, it is easy for human to take.
종래의 약탕기에서 다려 복용한 것보다는 약효가 월등한 것이다. 또한 도파민(dopamine)을 첨가하여 약효성분이 인체에 적용할 때 현저한 심혈관계 및 신장과 간장에 대한 혈액순환의 효과가 크게 향상됨을 발견하였다. 본 발명의 당초 개발 목표는 다음과 같다.The drug effect is superior to that taken in the conventional medicine bath. In addition, it was found that the addition of dopamine (dopamine) significantly improves the cardiovascular system and the effects of blood circulation on the kidneys and liver when the drug is applied to the human body. Initial development goals of the present invention are as follows.
이뇨작용(利尿作用), 간세포 신생촉진작용(肝細胞 新生促進作用), 청혈작용(淸血作用), 강심작용(强心作用), 고혈압강하(高血壓降下), 콜레스테롤(cholesterol)저하, 당뇨(糖尿), 관상동맥의 확장작용(冠狀動脈의 擴張作用), 뇌혈류량의 증가작용(腦血流量의 增加作用), 혈액순환개선작용(血液循環改善作用), 중풍(中風), 정력증강(精力增强), 간장보호(肝腸保護), 청열사화(淸熱瀉火), 청열해독(淸熱解毒), 양혈해독(血解毒), 지방간(脂肪肝), 자양강장작용(滋養强壯作用), 숙취해독(宿醉解毒) 및 피로회복(疲勞回復), 개선작용 등을 목표(目標)로 연구 개발한 약품이다.Diuretic effect (利 尿 作用), hepatocellular proliferation (肝 細胞 新生 促進 作用), blood clotting (淸 血 作用), cardiac action (强 心 作用), high blood pressure lowering (高血壓 降下), cholesterol lowering (cholesterol), diabetes (糖 尿), expansion of the coronary arteries (冠狀 張 作用), increased blood flow of the brain (腦 血流 作用), blood circulation improvement (血液 循環 改善 作用), stroke (中風), energy enhancement (精力, hepatoprotective, blue-heated fire, blue-heat detoxification, blood detoxification It is a drug that has been researched and developed for the purpose of 血 解毒, fatty liver, nourishing tonic effect, hangover detoxification, fatigue recovery, and improvement.
본 발명의 약 성분에은 자양강장작용, 항균작용, 청혈작용, 성기능 촉진작용, 혈당저하작용, 혈압강하작용 등 100여 종류의 약성분이 포함되어 있다. 이와같이 100여 종류의 약성분이 다 인체에 유효 작용케 함은 매우 어려운 과제였다. 그러나 약용 동ㆍ식물을 먼저 법제하였고 도파민(dopamine)과 디엘-아스파라긴(DL-Asparagine)을 첨가하므로서 완전히 해결하였다. 또한 약성분을 더 완벽하게 처리하기 위하여 추출전 50메쉬 정도의 분말로 하여 에틸알콜(Ethyl alcohol)과 접촉면을 넓혀 거의 완전히 추출하였다. 그러나 에틸알콜은 인화성(引火性) 물질로서 화기에 매우 위험한 것이다. 따라서 30-60% 알콜로 조정 사용하였다. 약용성분 액기스의 농축 과정에서 증발하는 알콜은 공해의 위험성이 상존한다. 이것은 대량생산시 시설을 보완하여 알콜을 회수하여 사용하면 되는 것이다. 특히 농축액을 건조하는 과정이 어려웠다. 섭씨 120℃ 이상에서는 약의 성분이 감소함을 발견하여 특수 건조기를 설계 완성하였다. 또한 약용 식물의 취급시 부가되는 오염물은 법제 과정에서 해결 할 수 있었다. 취급 과정에서 세균의 오염 역시 섭씨 120℃로 건조 하므로서 해결된 것이다. 다음은 약품의 부패에 대하여 염려가 되었다. 본 발명에서는 보존료를 사용하지 않기 때문이다. 그러나 약 성분중 항균작용 성분이 있기 때문에 농축액을 100% 건조시키므로 서 해결 할 수 있었다.The drug component of the present invention contains about 100 kinds of drug components such as nourishing tonic action, antibacterial action, blue blood action, sexual function promotion action, hypoglycemic action, blood pressure lowering action. As such, it was a very difficult task to have more than 100 kinds of medicines act effectively on the human body. However, medicinal plants and plants were first formulated and completely solved by the addition of dopamine and DL-Asparagine. In addition, in order to process the medicinal ingredients more completely, 50 mesh powder was extracted before extraction, and the contact surface with ethyl alcohol was broadened and almost completely extracted. However, ethyl alcohol is a flammable substance and is very dangerous to fire. Accordingly used with 30-60% alcohol. Alcohols that evaporate during the concentration of medicinal extracts present a risk of pollution. This is done by recovering alcohol and supplementing the facility in mass production. In particular, the process of drying the concentrate was difficult. Above 120 ° C, the medicinal component was found to be reduced, and a special dryer was designed and completed. In addition, contaminants added during the handling of medicinal plants could be solved during the legal process. Contamination of bacteria during handling was also solved by drying to 120 ° C. The following concerns about the corruption of the drug. This is because no preservative is used in the present invention. However, because of the antimicrobial activity among the drug ingredients were able to solve by drying the concentrate 100%.
1) A용기에 약용 식물의 약성분을 적당히 절편한 홍삼(紅蔘), 구기자(枸杞子), 영지(靈芝), 지구자(枳子), 청피(靑皮), 포공영(蒲公英), 치자(梔子), 갈근(葛根), 천궁(川芎)을 각각 50-70부씩 평량하여 취하고 3% 염수(鹽水), 400-600부, 탁주(에틸알콜 6%) 즉 막걸리 100-300부 그리고 우유 30-50부를 가하여 24시간 침전 시킨 후 가하여진 염수, 탁주 그리고 우유를 잘 흔들어 씻은 후 건져 건조시킨다. 건조 후 여기에 흑두(黑豆) 10-30부, 감초(甘草) 10-30부 그리고 증류수 700-900부를 취하여 약 2시간 서서히 가열한다. (콩이 익을 때까지) 콩이 완전히 익으면 가열을 중지하고 냉각시킨 후 가하여진 흑두와 감초를 제거하고 건조시킨다. 여기에 감초 50-70부를 가하여 50메쉬(mesh) 정도로 분쇄한 후 도파민(dopamine) 5-15부와 디엘-아스파라긴(DL-Asparagine) 10-30부 그리고 에틸알콜(Ethyl alcohol) 700-900부를 가하고 용기의 뚜껑을 밀폐시킨다. 15일 후면 수용성 및 유용성 약성분이 거의 다 추출되는 것이다. 이것을 여과하여 600-800부를 취득한다. 취득액을 다시 농축하고 이때 에틸알콜은 인화성이 있으므로 주의를 하여야 한다. 3시간 동안 90-100℃ 농축하였다. 이 농축된 것을 100-120℃의 건조기에서 5시간 완전 건조시킨 것이다. 이것을 200메쉬이상 분말로 하여 그 생성물로 한다.1) Red ginseng, Gugija, ganoderma lucidum, earthworm 50-70 parts by weight of each of Cheongpi, Cheongpi, Pogongyoung, Gardenia, Brown root, Cheongung, and 3% brine, 400-600 parts, Takju (ethyl alcohol 6%), namely 100-300 parts of makgeolli and 30-50 parts of milk was added to precipitate for 24 hours, and the salt, salt, and milk added were shaken well, washed and dried. After drying, 10-30 parts of black bean, 10-30 parts of licorice, and 700-900 parts of distilled water are taken and heated slowly for about 2 hours. When the beans are fully cooked, stop heating, cool, remove the black beans and licorice, and dry them. To this, 50-70 parts of licorice is added and pulverized to about 50 mesh. Then, 5-15 parts of dopamine, 10-30 parts of DL-Asparagine, and 700-900 parts of ethyl alcohol are added thereto. Seal the lid of the container. After 15 days, almost all of the water-soluble and oil-soluble drug ingredients are extracted. This is filtered to obtain 600-800 parts. Concentrate the obtained solution again, and care should be taken as ethyl alcohol is flammable. Concentrate at 90-100 ° C. for 3 hours. This concentrated product was completely dried in a dryer at 100-120 ° C. for 5 hours. This product is made into powder which is 200 mesh or more.
2) B용기에 약용 동ㆍ식물을 1)에서와 같이 산수유(山茱萸), 두충(杜), 동충하초(冬夏草), 구자(子), 오가피(五加皮), 당귀(當歸), 녹용(鹿茸)을 각각 40-60부씩 평량하여 취하고 3% 염수 300-500부, 탁주(에틸알콜 6%) 100-300부 그리고 우유 30-50부를 가하여 24시간 침전시킨 후 가하여진 염수, 탁주 그리고 우유를 잘 흔들어 씻은 후 건져 건조시킨다. 건조 후 여기에 감초(甘草) 40-60부를 가하여 50메쉬 정도로 분쇄한 후 도파민(dopamine) 1-10부와 디엘-아스파라긴(DL-Asparagine) 10-20부 그리고 에틸알콜(Ethyl alcohol) 500-700부를 가하고 용기의 뚜껑을 밀폐시킨다. 15일 후면 수용성 및 유용성 약성분이 거의 다 추출되는 것이다. 이것을 여과하여 400-600부를 취득하였다. 이 여과액을 3시간 동안 90-100℃로농축하였다. 이 농축된 것을 100-120℃의 건조기에서 5시간 건조한 후 200메쉬 이상으로 분쇄하여 그 생성물로 한다.2) Put medicinal animals and plants in container B as in 1) ), Cordyceps sinensis (冬) 夏 草), Guja ( Take 40-60 parts of oak, ogapi, Angelica and antler, weigh 300-500 parts of 3% brine, 100-300 parts of Takju (6% ethyl alcohol) and milk 30 Precipitate for 24 hours by adding -50 parts, shake the added brine, takju and milk well, and dry. After drying, 40-60 parts of licorice is added and pulverized to about 50 mesh. Then, 1-10 parts of dopamine, 10-20 parts of DL-Asparagine, and ethyl alcohol 500-700 Add and seal the lid of the container. After 15 days, almost all of the water-soluble and oil-soluble drug ingredients are extracted. This was filtered to obtain 400-600 parts. This filtrate was concentrated to 90-100 ° C. for 3 hours. The concentrated product was dried in a dryer at 100-120 ° C. for 5 hours, and then ground to 200 mesh or more to obtain the product.
3) C용기에 1)에서와 같이 산약(山藥), 진피(秦皮), 천문동(天門冬), 음양곽(淫羊藿), 백강잠(白蠶), 오미자(五味子), 금은화(金銀花)를 각각 30-50부씩 평량하여 취하고 3%염수 200-400부, 탁주 100-200부 그리고 우유 30-50부를 가하여 24시간 침전시킨 후 가하여진 염수, 탁주 그리고 우유를 잘 흔들어 씻은 후 건져 건조시킨다. 건조 후 여기에 흑두(黑豆) 30-50부 및 감초(甘草) 30-50부를 가하여 50메쉬 정도로 분쇄한 후 도파민(dopamine) 1-10부와 디엘-아스파라긴(DL-Asparagine) 10-20부 그리고 에틸알콜(Ethyl alcohol) 400-600부를 가하고 용기의 뚜껑을 밀폐시킨다. 15일 후면 수용성 및 유용성 성분이 거의 다 추출되는 것이다. 이것을 여과하여 300-500부를 취득하였다. 이 여과액을 3시간 동안 90-100℃로 농축하였다. 이 농축된 것을 100-120℃의 건조기에서 5시간 건조한 후 200메쉬 이상으로 분쇄하여 그 생성물로 한다. A용기, B용기, C용기 생성물을 잘 혼합ㆍ혼연(渾然)하여 최종 생성물로 한다.3) In the container C, as in 1), mountain medicine, Jinpi, Cheonmun-dong, Yin-Yang-Kwak, and Baekgang-Jam. -50) Take 30-50 parts of Omija and Geumhwa, respectively, and add 3% brine 200-400 parts, 100-200 parts of Takju and 30-50 parts of milk, and settle for 24 hours. Shake well, takju and milk, dry and dry. After drying, 30-50 parts of black bean and 30-50 parts of licorice are added and ground to 50 mesh, and then 1-10 parts of dopamine and 10-20 parts of DL-Asparagine, and Add 400-600 parts of ethyl alcohol and close the lid of the container. After 15 days, almost all of the water-soluble and oil-soluble components are extracted. This was filtered to obtain 300-500 parts. This filtrate was concentrated to 90-100 ° C. for 3 hours. The concentrated product was dried in a dryer at 100-120 ° C. for 5 hours, and then ground to 200 mesh or more to obtain the product. A, B, and C products are mixed and kneaded well to obtain the final product.
[실시예 1]Example 1
1) A용기에 약용 식물의 약성분을 적당히 절편한 홍삼, 구기자, 영지, 지구자, 청피, 포공영, 치자, 갈근, 천궁을 각각 600g씩 평량하여 취하고 3%염수 5,000cc, 탁주(에틸알콜 6%) 2,000cc 그리고 우유 400cc를 가하여 24시간 침전시킨 후 가하여진 염수, 탁주 그리고 우유를 잘 흔들어 씻은 후 건져 건조시킨다. 건조 후 여기에 흑두(검은콩) 200g, 감초 200g 그리고 증류수 8,000cc를 취하고 콩이 완전히 익을 때까지 가열하였다. 약 2시간 가열한 것이다. 콩이 완전히 익으면 가열을 중지하고 냉각시킨 후 가하여진 흑두와 감초를 제거하고 건져 건조시킨다. 여기에 감초 600g을 가하여 50메쉬 정도로 분쇄한 후 도파민 99g과 디엘-아스파라긴 198g 그리고 에틸알콜 8,000cc를 가하고 용기의 뚜껑을 밀폐시킨다. 15일 후 여과하여 약성분 액기스 7,000cc를 취득하였다. 이 취득액을 100℃로 3시간 농축하였다. 이 농축된 액을 건조기에서 5시간 완전 건조시킨 것이다. 이것을 200메쉬 이상으로 분쇄하여 고운분말 594g을 취득하였다.1) Take red ginseng, gojija, ganoderma lucidum, earthworm, cheongpi, pogongyoung, gardenia, brown root, and cheongung each weighing 600g each in container A. 3% saline 5,000cc, Takju (ethyl alcohol 6 %) Add 2,000cc and 400cc of milk and settle for 24 hours, shake the added brine, Takju and milk well, dry them after drying. After drying, 200 g of black bean (black bean), 200 g of licorice and 8,000 cc of distilled water were taken and heated until the beans were fully ripe. It was heated for about 2 hours. When the beans are fully cooked, stop heating, cool, remove the black beans and licorice, and dry them. Add 600 g of licorice and grind it to about 50 mesh, add 99 g of dopamine, 198 g of DL-asparagine, and 8,000 cc of ethyl alcohol, and seal the lid of the container. Filtration was carried out after 15 days to obtain 7,000cc of a weak ingredient extract. This acquisition liquid was concentrated to 100 degreeC for 3 hours. This concentrated liquid was completely dried in a dryer for 5 hours. This was ground to 200 mesh or more to obtain 594 g of fine powder.
2) B용기에 약용 동ㆍ식물을 1)에서와 같이 산수유, 두충, 동충하초, 구자, 오가피, 당귀, 녹용을 각각 500g씩 평량하여 취하고 3%염수 4,000cc, 탁주(에틸알콜 6%) 2,000cc 그리고 우유 400cc를 가하여 24시간 침전시킨 후 가하여진 염수, 탁주 그리고 우유를 잘 흔들어 씻은 후 건져 건조시킨다. 건조 후 여기에 감초 500g을 가하여 50메쉬 정도로 분쇄한 후 도파민(dopamine) 73g과2) Take medicinal animals and plants in B container as in 1), and weigh 500g of cornus oil, tofu, cordyceps, guja, agapi, donkey, and deer antler, respectively, 3% brine 4,000cc, Takju (ethyl alcohol 6%) 2,000cc Add 400cc of milk and settle for 24 hours, shake the added brine, takju and milk well, wash and dry. After drying, 500g of licorice is added and pulverized to about 50 mesh and 73g of dopamine
디엘-아스파라긴(DL-Asparagine)146g 그리고 에틸알콜(Ethyl alcohol) 6,000cc를 가하고 용기의 뚜껑을 밀폐시킨다. 15일 후 여과하여 약성분 액기스 5,000cc를 취득하였다. 이 취득액을 100℃로 3시간 농축하였다. 이 농축된 액을 건조기에서 5시간 완전 건조시킨 것이다. 이것을 200 메쉬이상으로 분쇄하여 고운분말 440g을 취득하였다.Add 146 g of DL-Asparagine and 6,000 cc of ethyl alcohol and seal the lid of the container. Filtration after 15 days to obtain 5,000 cc of drug extract. This acquisition liquid was concentrated to 100 degreeC for 3 hours. This concentrated liquid was completely dried in a dryer for 5 hours. This was ground to 200 mesh or more to obtain 440 g of fine powder.
3) C용기에 1)에서와 같이 산약, 진피, 천문동, 음양곽, 백강잠, 오미자, 금은화를 각각 400g씩 평량하여 취하고 3%염수 3,000cc, 탁주(에틸알콜 6%) 1,500cc그리고 우유 400cc를 가하여 24시간 침전시킨 후 가하여진 염수, 탁주 그리고 우유를 잘 흔들어 씻은 후 건져 건조시킨다. 건조 후 여기에 흑두(검은콩) 400g 및 감초 400g을 가하여 50메쉬 정도로 분쇄한 후 도파민(dopamine) 66g과 디엘-아스파라긴(DL-Asparagine) 132g 그리고 에틸알콜(Ethyl alcohol) 5,000cc를 가하고 용기의 뚜껑을 밀폐시킨다. 15일 후 여과하여 약성분 액기스 4,000cc를 취득하였다. 이 취득액을 100℃로 3시간 농축하였다. 이 농축된 액을 건조기에서 5시간 완전 건조시킨 것이다. 이것을 200메쉬 이상으로 분쇄하여 고운분말 396g을 취득하였다. A, B, C 용기의 취득 물을 잘 혼합ㆍ혼연(渾然)하여 최종으로 생성물 1,430g을 취득한 것이다. 이것을 캅셀(capsule)에 충진하여 2,860 캅셀 약품을 생산한 것이다.3) In the C container, take 400g each of powdered acid, dermis, astronomical dong, Yin Yang Kwak, Baekgangjam, Schisandra chinensis and Gold and Silver Coin as in 1), add 3% brine 3,000cc, 1,500cc Takju (6% ethyl alcohol) and 400cc milk. After settling for 24 hours, shake the added brine, takju and milk well, and dry them. After drying, 400g of black bean (black soybean) and 400g of licorice are pulverized to about 50 mesh, and then 66g of dopamine, 132g of DL-Asparagine and 5,000cc of ethyl alcohol are added to the lid of the container. Seal it. After 15 days, the solution was filtered to obtain 4,000 cc of drug substance extract. This acquisition liquid was concentrated to 100 degreeC for 3 hours. This concentrated liquid was completely dried in a dryer for 5 hours. This was ground to 200 mesh or more to obtain 396 g of fine powder. Acquisition of A, B, C containers The mixture was mixed and kneaded well, and finally 1,430 g of product was obtained. This was filled into capsules to produce 2,860 capsule medicines.
본 발명의 요약서 에서와 같이 100여 성분의 약효로서 이것을 대별하면 대보원기(大補元氣), 보폐익비(補肺益脾), 보신익정(補賢益精), 양간명목(養肝明目), 보중익기(補中益氣), 윤폐거담(潤肺祛痰), 청열사화(淸熱瀉火), 해주독(解酒毒), 청열해독(淸熱解毒), 양혈해독(血解毒), 해표투진(解表透疹), 활혈행기(活血行氣), 보익간신(補益肝賢), 강근골(强筋骨), 안태(安胎), 식풍해경(息風解痙), 화담산결(火痰散結), 거풍지통(祛風止痛), 거풍습(祛風濕), 보혈조경(補血調經), 활혈지통(活血止痛), 보비위(補脾胃), 익폐신(益肺腎), 자음(滋陰), 윤폐지해(潤肺止咳), 양음생진(養陰生津), 보신조양(補賢助陽), 자폐보신(滋肺補腎), 염폐자신(肺滋腎), 익신고정(益腎固精), 청간명목(淸肝明目), 신경계흥분작용(神經系興奮作用), 부신피질자극작용(副賢皮質刺戟作用), 성기능촉진작용(性機能促進作用), 강심작용(强心作用), 혈당저하작용(血糖低下作用), 식욕증진작용(食慾增進作用), 항아나필라씨스작용(抗 Anaphylaxis 作用), 항이뇨작용(抗利尿作用), 자양강장작용(滋養强壯作用), 간세포신생촉진작용(肝細胞新生促進作用), 해독작용(解毒作用), 코티코이드양작용(Corticoid 樣作用), 진경작용(鎭痙作用), 위산분비억제작용(胃酸分泌抑制作用), 거담작용(祛痰作用), 항염작용(抗炎作用), 발육촉진작용(發育促進作用), 조혈작용(造血作用), 건위작용(健胃作用), 발한작용(發汗作用), 항진균작용(抗眞菌作用), 해열작용(解熱作用), 관상동맥의 확장작용(冠狀動脈의 擴張作用), 뇌혈류량의 증가작용(腦血流量의 增加作用), 이담작용(利膽作用), 진정작용(鎭靜作用), 혈압강하작용(血壓降下作用), 자양작용(滋養作用), 혈관확장작용(血管擴張作用), 진통작용(鎭痛作用), 항트리코모나스작용(抗 Trichomonas 作用), 강장작용(强壯作用), 항바이러스작용(抗 Virus 作用), 지망간(脂肪肝), 진해작용(鎭咳作用), 소화촉진작용(消化促進作用), 기관지확장작용(氣管支擴張作用), 정력증강(精力增强), 통변작용(通便作用), 트랜사미나스저하작용(Transaminase 低下作用), 이완작용(弛緩作用), 숙취해독(宿醉解毒) 및 피로회복(疲勞回復) 개선 등을 목표(目標)로 연구 개발한 약품이다.As described in the summary of the present invention as a medicinal effect of about 100 ingredients, Daebowongi (大補 元氣), Bokbok Ikbi (補肺 益脾), Bosin Ikjeong (補 賢 益 精), nomenclature (양 明目) , Bojung Ikgi (補中益氣), Yunheol Geodam, Cheongyeolsahwa (淸 熱 瀉火), Haeju poison, Cheongyeol detoxification (양 解毒), Blood detoxification ( 해 解毒, Haedoptojin, Activation of blood circulation, Bowik Ganshin, Kang Geun-gol, Antae, Food style seascape ), Hwadam mountain, fire breeze, wind breeze, blood landscape, blood circulation, active blood pain, bowie stomach, pulmonary dysfunction (,), Consonant (윤), yunjijihae (潤肺 止咳), Yang Yin Shengjin, Boxin Chaoyang (신 陽), autism Bosin (염) 익, Ixin fixation, blue liver nominal, nervous system excitement, adrenal cortex stimulation, sexual function promoting機能 促進 作用, cardiovascular action, hypoglycemic action, appetite boosting effect (食 항 作用), anti-anaphylaxis action, antidiuretic action (抗 利 尿 作用) , Nourishing tonic (滋養 强壯 作用), hepatocellular proliferation (肝 細胞 新生 促進 作用), detoxification (解毒 作用), corticoids (Corticoid, 作用), jingyeong (, 作用), stomach acid secretion inhibitory Action (거 分 거 制作 用), expectorant action (祛痰 作用), anti-inflammatory action (抗炎 作用), growth promoting action (發育 促進 作用), hematopoietic action (用 作用), dry stomach action (健胃 作用), sweating (發汗 作用), antifungal action (抗 眞 菌 作用), antipyretic action (解熱 作用), coronary artery dilatation action (作 動作 用 用), increase in blood flow to the brain (腦 血流增加 作用), Idam effect (利膽 作用), sedation (鎭 靜 作用), blood pressure lowering (血壓 降下 作用), nourishing (滋養 作用), vasodilation (血管 擴張 作用), analgesic action (鎭 痛 作用, anti-trichomonas action (抗 用 用), tonic action (强壯 作用), antiviral action (抗 Virus 作用), Jimangan (脂肪 肝), Jinhae effect (鎭 咳 作用), digestion promoting action (消化促進 作用, bronchial dilatation (氣管 支 擴張 作用), energetic strengthening (精力 통), transmutation (通便 作用), transsaminase lowering (Transaminase, 下 作用), relaxation (弛緩 作用), hangover detoxification ( It is a drug researched and developed with the goal of improving 및 解毒 and fatigue recovery.
본 발명품을 숙취 해독 및 피로회복 개선을 위한 건강음료로 제품화한다면 그 활용범위는 더욱 더 확대될 것이다.If the present invention is commercialized as a health drink for improving hangover detoxification and fatigue recovery, the scope of application will be further expanded.
자체임상실험 예 (시험용" NANOPASS " 복용자의 말씀)Self-clinical experiment example (for test "NANOPASS" taker)
1) 60세의 남자 분은 몸이 매우 허약하여 계단을 오르고 내리기가 힘들 정도로 몸이 허약하여 피로감을 쉽게 느꼈는 데 본 제품을 1개월 복용한 후 피로회복 개선효과를 보았고 매사에 자신감을 갖고 생활 할 수 있다고 함.1) The 60-year-old man was very weak and was too weak to climb or descend the stairs and felt tired easily. After taking this product for 1 month, he saw improvement in fatigue recovery and was able to live with confidence in everything. It can be said.
2) 50세의 직장 중년 부인은 하루 일과 중 오후 시간이 되면 매사에 무기력 감을 느끼고 피곤해 했는데 본 제품을 1개월 복용한 후 삶의 활력을 찾아 매사에 기쁜 마음으로 하루 일과를 보낼 수 있다고 함.2) A 50-year-old middle-aged woman feels helpless and tired when everything is in the afternoon hours of the day, but after taking this product for a month, she can spend her day happily looking for the vitality of life.
3) 45세의 중년 남성은 1주일에 5일 정도는 과음을 하는데 그 숙취피로감으로 인해 매우 힘들다고 하여 본 제품을 술마시기전과 술마시고난 후 복용해 보라고 권유한 결과 숙취해독은 물론 두통과 육체의 피로감도 해결 할 수 있었다고 함.3) A 45-year-old middle-aged man has excessive drinking for 5 days a week, and because of the hangover fatigue, it is very hard to take this product before drinking and after drinking. The fatigue could be solved.
4) 남(男) 녀(女) 공히 술마시고난 후 숙취로 인해 속이 매시껍고 두통이 심해 몹시 힘이 들었는데 본 제품을 복용하고 난 후 숙취해독의 개선 효과가 있었다고 함.4) After drinking both men and women, the hangover caused severe mash and severe headaches, and it was very hard. After taking this product, the hangover detoxification effect was improved.
5) 본 발명 견본품 복용자가 100여명이 된바 이대로라도 좋으니 판매하기를 원하였으나 정식 제품이 아니기 때문에 판매가 불가능하였으나 이 약품에 자신감을 갖고 발명특허를 출원하기에 이름.5) The sample taker of the present invention has been more than 100 people wanted to sell as it is good, but because it is not a formal product was not available for sale, but with confidence in this drug, the name for filing an invention patent.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020018765A KR20030079604A (en) | 2002-04-04 | 2002-04-04 | The composition of improved materials in treating alcohol hangover and boosting an energy. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020018765A KR20030079604A (en) | 2002-04-04 | 2002-04-04 | The composition of improved materials in treating alcohol hangover and boosting an energy. |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20030079604A true KR20030079604A (en) | 2003-10-10 |
Family
ID=32378009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020020018765A KR20030079604A (en) | 2002-04-04 | 2002-04-04 | The composition of improved materials in treating alcohol hangover and boosting an energy. |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20030079604A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020062899A (en) * | 2002-07-04 | 2002-07-31 | 서봉석 | Health food based on red ginseng and Cordyceps sinensis |
CN102552493A (en) * | 2012-02-02 | 2012-07-11 | 贵州益佰制药股份有限公司 | Anti-inebriation drunk-preventing composition and preparation method thereof |
KR101281988B1 (en) * | 2010-06-23 | 2013-07-03 | (주)새롬바이오 | Composition having eleutherococcus senticosus for treating hangover and improving liver function, and the preparation method thereof |
CN104547537A (en) * | 2013-10-12 | 2015-04-29 | 青岛锦涟鑫商贸有限公司 | Foot bath bag for relieving fatigue |
KR101961788B1 (en) * | 2018-06-15 | 2019-03-25 | 농업회사법인정담아(주) | Alcohol detoxification beverage composition comprising extract of asparagus tuber |
CN109602721A (en) * | 2019-01-22 | 2019-04-12 | 海南仙草南芝生物科技有限公司 | A kind of toxin expelling protect liver, the ganoderma lucidum herb essence soft capsule for improving capability of resistance to radiation, inhibiting tumour |
WO2019225653A1 (en) * | 2018-05-23 | 2019-11-28 | 花王株式会社 | Gip elevation inhibitor |
CN114129580A (en) * | 2021-12-24 | 2022-03-04 | 西安荷默奇医药科技有限公司 | Traditional Chinese medicine-based component composition and application thereof in treating depression |
CN114747707A (en) * | 2022-04-24 | 2022-07-15 | 中国农业科学院都市农业研究所 | Eucommia male flower anti-alcohol composition and preparation method thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR910002461A (en) * | 1989-07-06 | 1991-02-25 | 유광근 | Alcoholic beverage additives and method for manufacturing hangover |
KR950007867A (en) * | 1993-09-22 | 1995-04-15 | 성우경 | Herbal composition for prevention and treatment of hangover symptoms |
KR100232987B1 (en) * | 1996-01-18 | 2000-02-01 | 이상준 | Tonic composition and tonic including the same |
KR20000066984A (en) * | 1999-04-22 | 2000-11-15 | 안상태 | composition for dissolving hangover and uric acid replacement defect and its manufacturing process |
KR20010113408A (en) * | 2000-06-19 | 2001-12-28 | 이원송 | Compositions of drug for improvement of impotency and the circulation of the blood |
KR100379973B1 (en) * | 2000-11-28 | 2003-04-16 | 김현영 | Chinese Medicine Composition for Dissolving Suffer from Aftereffects of Drink and Method of Preparing the Same |
KR101094961B1 (en) * | 2011-06-13 | 2011-12-15 | 한국기계연구원 | Vacuum hot pressing diffusion bonding apparatus |
-
2002
- 2002-04-04 KR KR1020020018765A patent/KR20030079604A/en not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR910002461A (en) * | 1989-07-06 | 1991-02-25 | 유광근 | Alcoholic beverage additives and method for manufacturing hangover |
KR950007867A (en) * | 1993-09-22 | 1995-04-15 | 성우경 | Herbal composition for prevention and treatment of hangover symptoms |
KR100232987B1 (en) * | 1996-01-18 | 2000-02-01 | 이상준 | Tonic composition and tonic including the same |
KR20000066984A (en) * | 1999-04-22 | 2000-11-15 | 안상태 | composition for dissolving hangover and uric acid replacement defect and its manufacturing process |
KR20010113408A (en) * | 2000-06-19 | 2001-12-28 | 이원송 | Compositions of drug for improvement of impotency and the circulation of the blood |
KR100379973B1 (en) * | 2000-11-28 | 2003-04-16 | 김현영 | Chinese Medicine Composition for Dissolving Suffer from Aftereffects of Drink and Method of Preparing the Same |
KR101094961B1 (en) * | 2011-06-13 | 2011-12-15 | 한국기계연구원 | Vacuum hot pressing diffusion bonding apparatus |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020062899A (en) * | 2002-07-04 | 2002-07-31 | 서봉석 | Health food based on red ginseng and Cordyceps sinensis |
KR101281988B1 (en) * | 2010-06-23 | 2013-07-03 | (주)새롬바이오 | Composition having eleutherococcus senticosus for treating hangover and improving liver function, and the preparation method thereof |
CN102552493A (en) * | 2012-02-02 | 2012-07-11 | 贵州益佰制药股份有限公司 | Anti-inebriation drunk-preventing composition and preparation method thereof |
CN104547537A (en) * | 2013-10-12 | 2015-04-29 | 青岛锦涟鑫商贸有限公司 | Foot bath bag for relieving fatigue |
WO2019225653A1 (en) * | 2018-05-23 | 2019-11-28 | 花王株式会社 | Gip elevation inhibitor |
CN112153965A (en) * | 2018-05-23 | 2020-12-29 | 花王株式会社 | GIP elevation inhibitor |
KR101961788B1 (en) * | 2018-06-15 | 2019-03-25 | 농업회사법인정담아(주) | Alcohol detoxification beverage composition comprising extract of asparagus tuber |
CN109602721A (en) * | 2019-01-22 | 2019-04-12 | 海南仙草南芝生物科技有限公司 | A kind of toxin expelling protect liver, the ganoderma lucidum herb essence soft capsule for improving capability of resistance to radiation, inhibiting tumour |
CN109602721B (en) * | 2019-01-22 | 2021-04-02 | 海南仙草南芝生物科技有限公司 | Ganoderma lucidum whole plant essence soft capsule for expelling toxin, protecting liver, improving radiation resistance and inhibiting tumor |
CN114129580A (en) * | 2021-12-24 | 2022-03-04 | 西安荷默奇医药科技有限公司 | Traditional Chinese medicine-based component composition and application thereof in treating depression |
CN114129580B (en) * | 2021-12-24 | 2024-05-10 | 海南云泽医药科技有限公司 | Traditional Chinese medicine-based component composition and application thereof in treating depression |
CN114747707A (en) * | 2022-04-24 | 2022-07-15 | 中国农业科学院都市农业研究所 | Eucommia male flower anti-alcohol composition and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101513437B (en) | Antifatigue Chinese pharmaceutical composition and preparation method thereof | |
KR20100022539A (en) | The composition of drug for improvement of impotency and circulation of blood | |
CN111227239A (en) | Deer blood freeze-dried powder soft capsule for tonifying qi and blood, resisting aging and nourishing ovary and preparation method thereof | |
KR20030079604A (en) | The composition of improved materials in treating alcohol hangover and boosting an energy. | |
CN103749821B (en) | A kind of gynostemma pentaphylla health-care tea improving immunity and preparation method thereof | |
KR20100036820A (en) | The invigorate energy food which is made from herb medicine and the producing method thereof | |
CN108041391A (en) | A kind of Black people join theanine drink and preparation method thereof | |
KR20050001556A (en) | The composition of materials to prevent the adult disease and reduce the obesity | |
CN107519310B (en) | Improve Chinese medicine composition and preparation process that energy inhibits growth of tumour cell function | |
CN110810693A (en) | A beverage composition containing Ampelopsis grossedentata and its preparation method | |
CN108850319A (en) | A kind of preparation method with health functions instant tea powder | |
CN103142848B (en) | Anti-aging Chinese medicine preparation and preparation method thereof | |
CN112494414A (en) | Traditional Chinese medicine compound with whitening and anti-aging effects and preparation method thereof | |
CN106215118A (en) | Antineoplastic health preparation and preparation method thereof | |
CN108261428A (en) | A kind of preparation method of Antrodia camphorata dripping pill | |
KR101629542B1 (en) | method for extracting hair growth promoting components | |
KR101273327B1 (en) | Manufacturing method of composition of enzyme for coffee creamer replacement, composition of enzyme for coffee creamer replacement manufactured by the same and enzyme coffee mix using thereof | |
CN112076292A (en) | Powder with functions of enhancing immunity and regulating kidney yin deficiency and preparation method thereof | |
CN116942763B (en) | Traditional Chinese medicine composition for nourishing yin and strengthening spleen, tablet candy, preparation method and application | |
KR102485019B1 (en) | Functional leached tea and manufacturing method of the same | |
CN108379446A (en) | Co-enzyme Q 10 formulations and preparation method thereof with auxiliary treatment male's teen bra | |
CN108452079B (en) | Methods and compositions for delaying senescence, inhibiting tumor cell growth, and improving microcirculation | |
CN112717074B (en) | Medicated wine for preventing and treating alopecia and preparation method | |
CN111218338A (en) | Extraction method of dogwood volatile oil | |
CN102860507A (en) | Novel grape seed extract and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |